Search for 'Provider:British journal of haematology,'

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín | Fernández Redondo, Elena. British Journal of Haematology, 2013 . 163(2):223-34. , Formato Vancouver: Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B et al. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. Br J Haematol. 2013 Oct;163(2):223-34.

Place Hold on Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP/ALL-2005.

By Vivanco Martínez, José Luis. British Journal of Haematology, 2013 . 162(3):419-21. , Formato Vancouver: Rives S, Camós M, Estella J, Gómez P, Moreno MJ, Vivanco JL et al. Spanish Paediatric Haemato-Oncology Group (SHOP/ SEHOP). Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP/ALL-2005. Br J Haematol. 2013 Aug;162(3):419-21.

Place Hold on Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP/ALL-2005.

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

By Ayala Díaz, Rosa María | Fernández Redondo, Elena | Lahuerta Palacios, Juan José | Martínez López, Joaquín | Martínez Sánchez, María Pilar | Montalbán Pallarés, María Ángeles. British Journal of Haematology, 2013 . 163(5):581-9. , Formato Vancouver: Martínez López J, Fernández Redondo E, García Sanz R, Montalbán MA, Martínez Sánchez P, Pavia B, et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol. 2013;163(5):581-9.

Place Hold on Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

The homozygous mutation G75R in the human SLC11A2 gene leads to microcytic anaemia and iron overload.

By Baro Fernández, María | Barrios López, Marta | Cuadrado Grande, Nuria | Morán Jiménez, María Josefa | Moreno Carralero, María Isabel | Vivanco Martínez, José Luis. British Journal of Haematology, 2012 . 157(4):514-6. , Formato Vancouver: Barrios M, Moreno-Carralero MI, Cuadrado-Grande N, Baro M, Vivanco JL, Morán-Jiménez MJ. The homozygous mutation G75R in the human SLC11A2 gene leads to microcytic anaemia and iron overload. Br J Haematol. 2012 May;157(4):514-6.

Place Hold on The homozygous mutation G75R in the human SLC11A2 gene leads to microcytic anaemia and iron overload.

Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.

By Serna Torroba, Javier de la . British Journal of Haematology, 2012 . 157(1):67-74. , Formato Vancouver: Delgado J, Espinet B, Oliveira AC, Abrisqueta P, de la Serna J, Collado R, et al. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol. 2012 Apr;157(1):67-74.

Place Hold on Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.

Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.

By Ayala Díaz, Rosa María | Canal López, Alicia | Castro Quismondo, Nerea | Grande García, Carlos | Martínez López, Joaquín | Rueda Fernández, Daniel. British Journal of Haematology, 2012 . 158(4):555-8. , Formato Vancouver: Martínez-López J, Castro N, Rueda D, Canal A, Grande C, Ayala R. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. Br J Haematol. 2012 Aug;158(4):555-8.

Place Hold on Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.

Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005

By Vivanco Martínez, José Luis. British Journal of Haematology, 2011 . 154(5):600-611. , Formato Vancouver: Rives S, Estella J, Gómez P, López-Duarte M, de Miguel PG, Verdeguer A, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol. 2011;154(5):600-11.

Place Hold on Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.

By Lahuerta Palacios, Juan José . British journal of haematology, 2015 . 170(6):804-13. , Formato Vancouver: Cibeira MT, Oriol A, Lahuerta JJ, Mateos MV, de la Rubia J, Hernández MT et al; PETHEMA cooperative study group. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015 Sep;170(6):804-13.

Place Hold on A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.

CALR mutations screening should not be studied in splanchnic vein thrombosis.

By Castro Quismondo, Nerea | Rapado Martínez, Inmaculada | Ayala Díaz, Rosa María | Martínez López, Joaquín. British journal of haematology, 2015 . 170(4):588-9. , Formato Vancouver: Castro N, Rapado I, Ayala R, Martínez López J. CALR mutations screening should not be studied in splanchnic vein thrombosis. Br J Haematol. 2015 Aug;170(4):588-9.

Place Hold on CALR mutations screening should not be studied in splanchnic vein thrombosis.

Use of eltrombopag after romiplostim in primary immune thrombocytopenia.

By Alonso Fernández, Rafael Alberto. British journal of haematology, 2015 . 169(1):111-6. , Formato Vancouver: González Porras JR, Mingot Castellano ME, Andrade MM, Alonso R, Caparrós I, Arratibel MC et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015 Apr;169(1):111-6.

Place Hold on Use of eltrombopag after romiplostim in primary immune thrombocytopenia.

A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.

By Martínez Sánchez, María Pilar. British journal of haematology, 2016 . 174(5):700-10. , Formato Vancouver: Bergua JM, Montesinos P, Martinez Cuadrón D, Fernández Abellán P, Serrano J, Sayas MJ et al; PETHEMA group. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2016 Sep;174(5):700-10.

Place Hold on A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.

By Martínez López, Joaquín. British journal of haematology, 2016 . 175(3):448-56. , Formato Vancouver: Mateos MV, Granell M, Oriol A, Martínez López J, Blade J, Hernandez MT et al. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016 Nov;175(3):448-56.

Place Hold on Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.